Sections

Home

Personal tools

You are here: Home → 2009 Symposia → XI International Symposium on Respiratory Viral Infections → Oral abstracts → Vaccination approaches to combat human metapneumovirus lower respiratory tract infections

The Macrae Group LLC

Lymphopenia in H5N1 patients in Northern Viet Nam: kinetics and subsets
Title of Contribution: A prospective cohort study of the seasonality and burden of pediatric influenza in Nicaragua
Characterisation of Influenza H1N1 viruses resistant to Oseltamivir
Paradoxical Generalized Decrease of Influenza-Specific T-Cell Responses in HIV-Infected Children after Administration of Inactivated Influenza Vaccine and Sporadic Decrease after Live Attenuated Influenza Vaccine
The relation between viral shedding and clinical course in natural influenza infections
Development of a Multiplexed Luminex xMap Assay for Serotype Specific Detection of Five Human Adenoviruses that cause Respiratory Illness.
Preexisting immunity to diverse respiratory adenovirus serotypes among young adults in the United States, 1998-2008
The PB1-F2 protein of influenza A virus modulates the early immune response leading to increased pathogenesis in the mouse model.
Genetic clustering of human rhinovirus strains in infants with severe bronchiolitis
Cross-reactive immunity of Influenza A/H5N1 strains in mice & humans
Ocular infection of mice with influenza A (H7) viruses: A site of primary virus replication and spread to the respiratory tract.
Nature and Impact of Influenza Antigen Specific T Cell Responses on Disease in an In Vivo Human Challenge Model.
Prospective Cohort Study of Avian Influenza Transmission in Cambodia and Thailand
Safety and Efficacy of Multiple-Day Treatment with Intravenous Peramivir or Oral Oseltamivir in Hospitalized Adults with Acute Influenza
Oseltamivir prophylaxis significantly reduces the incidence of seasonal influenza infection in immunocompromized patients
Anti-Influenza Serum and Mucosal Antibody Responses after Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-Infected Children
The Global Emergence and Evolution of Adamantane Resistant A/H3N2 Influenza Viruses
Maternal Influenza immunization and Birth Weights: A Randomized Trial in Bangladesh
Cystus052 a new compound against seasonal and pandemic influenza virus
Safety and Immunogenicity of an AS03-adjuvanted H5N1 Prepandemic Influenza Vaccine –A Phase III Study in Thai Population
An Early Report from a Randomized Controlled Trial of Nonpharmaceutical Interventions to Reduce Household Influenza Transmission; the Bangkok HITS Study
Combinations of immunomodulators and specific antivirals: A new treatment paradigm for Influenza
Antiviral Control of Influenza in Aged-Care facilities in Sydney region over 3 seasons
Rhinovirus infection augments recruitment of Th2 allergen specific T cells to the airway
Vaccination approaches to combat human metapneumovirus lower respiratory tract infections
Clinical features of human influenza A(H5N1) infection in Vietnam: 2004-2006
Oseltamivir pharmacokinetics in Vietnamese patients with severe human and H5N1 avian influenza.

Vaccination approaches to combat human metapneumovirus lower respiratory tract infections

Session VI – Herfst, Sander

Title of Contribution: Vaccination approaches to combat human metapneumovirus lower respiratory tract infections
Author(s): S. Herfst1, M. de Graaf1, E.J.A. Schrauwen1, A.S. Barnes2, K. Senthil2, N.D. Ulbrandt2, B.G. Van den Hoogen1, R.L. de Swart1, A.D.M.E. Osterhaus1 and R.A.M. Fouchier1
Affiliation(s): 1Department of Virology, Erasmus MC, Rotterdam, The Netherlands and 2MedImmune, Inc., 1 MedImmune Way, Gaithersburg, MD 20878, USA

Abstract:
Human metapneumovirus (HMPV) was discovered in 2001 as a causative agent of respiratory disease in young children, immunocompromised individuals and the elderly. Clinical signs of HMPV infection range from mild respiratory illness to bronchiolitis and pneumonia. Two main genetic lineages of HMPV that circulate worldwide were found to be antigenically different, but antibodies against the F protein, the major determinant of protection, were shown to be cross-protective. We recently showed that infection with HMPV induces only transient protective immunity, which could impede vaccine development.
To date, several research groups have developed a variety of vaccine candidates, exploring different strategies that may be used to protect the different risk groups against HMPV-induced respiratory disease. The studies in rodent and non-human primate models look promising, but none of the vaccine candidates has been tested yet in human volunteers. We will discuss our results obtained with immunization experiments using live attenuated viruses and subunit vaccines in rodents and non-human primates. Furthermore we will give an overview of the immunogenicity and protective efficacy of a variety of live attenuated, virus vectored, inactivated virus and subunit vaccines that have been tested in animal models.

Document Actions

« September 2010 »

Abstract format

(Word Document)

title
author(s)
author(s) affiliation(s)
abstract

Typed as follows

single-space
Times New Roman or Arial
11 or 12 point
1 page
1.5 inch (3.8 cm) top and bottom margins

Provide the details

presenting author
address/email address
session for abstract consideration